- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Announces Second Approval of Gavreto
New indication focuses on metastatic rearranged during transfection fusion-positive non-small cell lung cancer.
After previously approving Gavreto (pralsetinib) for non-small cell lung cancer (NSCLC) in late 2020, the FDA has announced an additional approval for metastatic rearranged during transfection (RET) fusion-positive NSCLC. Backed by an FDA-approved test, efficiency was demonstrated in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC. Patients received pralsetinib until disease progression or unacceptable toxicity, according to an FDA press release.
In the same press release, the FDA stated that the recommended pralsetinib dose is 400 mg orally once daily, to be taken on an empty stomach.
Reference: FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions. FDA. August 9, 2023. Accessed August 10, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
